Tag: cancer immunotherapy market share

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Cancer Immunotherapy Market Size Forecast: How Big Could The Market Get By 2030?

The cancer immunotherapy market size has seen rapid expansion over recent years. It is anticipated to expand from $124.09 billion in 2025 to $137.99 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.2%. The historical growth of this market can be linked to several factors, including major advancements in tumor immunology, a rise in global cancer incidence, the early efficacy of monoclonal antibodies, enhanced funding for oncology research and development, and the regulatory approvals granted for checkpoint inhibitors.

The cancer immunotherapy market size is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $210.39 billion in 2030, achieving a compound annual growth rate (CAGR) of 11.1%. This expansion during the forecast period can be attributed to factors such as the increasing adoption of CAR T-cell therapies, the extension into solid tumor indications, heightened investment in cancer vaccines, a growing demand for targeted combination therapies, and supportive reimbursement policies for immunotherapy. Significant trends expected in this period include the rapid embrace of immune checkpoint inhibitors, an expanding use of combination immunotherapy regimens, the proliferation of cell-based cancer therapies, an increasing focus on personalized immunotherapy, and a rising number of oncology clinical trials.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Cancer Immunotherapy Market Growth Catalysts And Demand Drivers

The projected increase in cancer cases is anticipated to drive growth in the cancer immunotherapy market. Globally, several factors such as tobacco use, alcohol consumption, obesity, inactive lifestyles, and environmental elements are contributing to the rise in cancer diagnoses. This surge in cancer occurrences is projected to stimulate demand for cancer immunotherapies, given that patients are increasingly seeking medical treatments offering improved recovery rates and reduced discomfort. For example, in July 2024, Cancer Research UK, a UK-based cancer charity, published projections indicating that cancer incidence rates in the United Kingdom are forecast to rise for the majority of cancer types between 2023-2025 and 2038-2040. These increases are expected to range from less than 1% for breast cancer to 50% for eye cancer. Conversely, a limited number of cancers are predicted to decrease, with reductions from 2% for lung cancer to 27% for mesothelioma. Consequently, the expanding incidence of cancer is anticipated to elevate the demand for cancer immunotherapy throughout the forecast period.

Cancer Immunotherapy Market Segment Analysis And Revenue Potential

The cancer immunotherapy market covered in this report is segmented –

1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy

2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma

3) By End User: Hospitals, Cancer Research Centers, Clinics

Subsegments:

1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies

2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists

4) By Vaccines: Therapeutic Cancer Vaccines

5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy

Cancer Immunotherapy Market Trends Shaping Long-Term Demand

Leading companies in the cancer immunotherapy market are concentrating on developing innovative solutions, such as PD-1 immunotherapies, to enhance the availability of advanced immune-based treatment options for patients suffering from hard-to-treat cancers. A PD-1 immunotherapy is a treatment designed to target immune checkpoints, stimulating antitumor immune activity by blocking interactions in the programmed death-1 pathway. For instance, in August 2025, Intas Pharmaceuticals, an India-based pharmaceutical firm specializing in oncology and biologics, launched HETRONIFLY (Serplulimab). This therapy is the world’s first programmed death-1 inhibitor approved for extensive-stage small cell lung cancer and operates via a dual mechanism targeting PD-L1 and PD-L2, with strong receptor internalization to boost immune engagement. Its demonstrated benefits in terms of survival and substantially reduced cost compared to existing immunotherapies emphasize its clinical value and widen patient access to advanced cancer treatment in India.

Cancer Immunotherapy Market Key Players Shaping Industry Direction

Major companies operating in the cancer immunotherapy market are Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc., Kura Oncology Inc.

View The Full Cancer Immunotherapy Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Cancer Immunotherapy Market Geographic Distribution And Regional Opportunities

North America was the largest region in the cancer immunotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Cancer Immunotherapy Market Revenue Growth Supported By A CAGR Of 210.38% Through 2030

The cancer immunotherapy market has experienced significant expansion in recent years. Projected to rise from $124.09 billion in 2025 to $137.99 billion in 2026, this growth reflects a compound annual growth rate (CAGR) of 11.2%. Historical progress has been driven by advances in tumor immunology, a growing worldwide cancer burden, the initial achievements of monoclonal antibodies, heightened investment in oncology research and development, and the regulatory clearance of checkpoint inhibitors.

The cancer immunotherapy sector is projected to experience substantial growth over the coming years, with its value anticipated to reach $210.39 billion by 2030, driven by a compound annual growth rate (CAGR) of 11.1%. This expansion during the forecast period is fueled by several key factors, such as the increasing implementation of CAR T-cell therapies, the broadening application of these treatments into solid tumor indications, heightened financial commitments directed toward cancer vaccine development, a growing demand for targeted combination therapeutic approaches, and the establishment of favorable reimbursement policies specifically designed to support immunotherapy modalities. Significant trends shaping this forward-looking landscape include the widespread adoption of immune checkpoint inhibitors, the escalating utilization of diverse combination immunotherapy regimens, the broadened deployment of cell-based therapeutic strategies, an intensified emphasis on delivering personalized immunotherapy solutions, and a notable increase in the volume of oncology-focused clinical trials being conducted.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Cancer Immunotherapy Market Growth Drivers: What Factors Are Accelerating Expansion?

An anticipated rise in the number of cancer cases is set to drive growth in the market for cancer immunotherapies. Globally, cancer incidence is being fueled by factors such as tobacco use, alcohol consumption, obesity, sedentary habits, and environmental influences. This uptick is expected to heighten the demand for cancer immunotherapies, as patients increasingly turn to treatments that offer better recovery rates and reduced discomfort. To illustrate, projections from Cancer Research UK—a British cancer charity—released in July 2024 indicate that cancer incidence rates in the UK are likely to rise for most types between 2023-2025 and 2038-2040, with increases varying from under 1% for breast cancer to 50% for eye cancer, while a few cancers are predicted to drop, such as a 2% decline in lung cancer and a 27% fall in mesothelioma. Consequently, this growing incidence of cancer is poised to boost the need for cancer immunotherapies throughout the forecast period.

Cancer Immunotherapy Market Categorization By Product Type And Application

The cancer immunotherapy market covered in this report is segmented –

1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy

2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma

3) By End User: Hospitals, Cancer Research Centers, Clinics

Subsegments:

1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies

2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists

4) By Vaccines: Therapeutic Cancer Vaccines

5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy

Cancer Immunotherapy Market Trends: What Is Shaping Future Industry Growth?

Major players within the cancer immunotherapy sector are concentrating on creating cutting-edge solutions, including PD-1 immunotherapies, to improve access to sophisticated immune-based treatments for patients with difficult-to-treat cancers. A PD-1 immunotherapy represents a treatment aimed at immune checkpoint pathways, crafted to stimulate antitumor immune responses by hindering programmed death-1 pathway interactions. For example, in August 2025, Intas Pharmaceuticals, an India-based firm specializing in oncology and biologics, introduced HETRONIFLY (Serplulimab). This therapy stands as the first programmed death-1 inhibitor authorized globally for extensive-stage small cell lung cancer, employing a dual mechanism that targets PD-L1 and PD-L2 while relying on strong receptor internalization to boost immune engagement. Its demonstrated survival advantages—combined with a noticeably lower cost compared to existing immunotherapies—highlight its clinical significance and expand patient access to advanced cancer care within India.

Cancer Immunotherapy Market Company Landscape And Strategic Competition

Major companies operating in the cancer immunotherapy market are Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc., Kura Oncology Inc.

Access The Complete Cancer Immunotherapy Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Cancer Immunotherapy Market Geographic Analysis: Where Is Demand Growing The Fastest?

North America was the largest region in the cancer immunotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Increase In Market Value Is Predicted For The Cancer Immunotherapy Market During The 2026–2030 Period?

The cancer immunotherapy market has experienced rapid expansion in recent years. It is projected to increase from $124.09 billion in 2025 to $137.99 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.2%. This historical growth can be attributed to significant advancements in tumor immunology, a global rise in cancer incidence, the early efficacy of monoclonal antibodies, increased funding for oncology research and development, and regulatory clearances for checkpoint inhibitors.

The cancer immunotherapy market size is projected for substantial growth over the upcoming years. It is anticipated to reach $210.39 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.1%. This expansion during the forecast period is fueled by factors such as the increasing acceptance of CAR T-cell therapies, the broadening of applications into solid tumor indications, heightened investment in cancer vaccines, a growing need for targeted combination therapies, and supportive reimbursement frameworks for immunotherapy. Key developments expected during this period involve the accelerated uptake of immune checkpoint inhibitors, a rise in the application of combination immunotherapy regimens, the extension of cell-based cancer therapies, an increased emphasis on personalized immunotherapy, and a surge in oncology clinical trials.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp

What Core Drivers Are Transforming The Cancer Immunotherapy Market?

The increasing occurrence of cancer is expected to drive growth in the cancer immunotherapy market. Global cancer cases are on the rise due to factors such as tobacco use, alcohol consumption, obesity, inactive lifestyles, and environmental influences. This growth in cancer incidence is anticipated to boost the need for cancer immunotherapies, as patients are increasingly seeking medical treatments that offer improved recovery and reduced discomfort. For example, in July 2024, according to forecasts released by Cancer Research UK, a UK-based cancer charity, cancer incidence rates in the United Kingdom are projected to increase for most types between 2023-2025 and 2038-2040, with rises varying from less than 1% for breast cancer to 50% for eye cancer. Conversely, a smaller number of cancers are expected to decline, with reductions ranging from 2% for lung cancer to 27% for mesothelioma. Consequently, the expanding incidence of cancer is predicted to fuel demand for cancer immunotherapy throughout the forecast period.

How Is The Cancer Immunotherapy Market Examined Through Segment Analysis?

The cancer immunotherapy market covered in this report is segmented –

1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy

2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma

3) By End User: Hospitals, Cancer Research Centers, Clinics

Subsegments:

1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies

2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists

4) By Vaccines: Therapeutic Cancer Vaccines

5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy

Which Trends Are Supporting The Evolution Of The Cancer Immunotherapy Market?

Leading companies in the cancer immunotherapy market are concentrating on developing innovative solutions, such as PD-1 immunotherapies, to broaden the availability of advanced immune-based treatment options for patients with challenging cancers. A PD-1 immunotherapy is an immune checkpoint-targeting treatment designed to stimulate antitumor immune activity by blocking programmed death-1 pathway interactions. For instance, in August 2025, Intas Pharmaceuticals, an India-based pharmaceutical company specializing in oncology and biologics, introduced HETRONIFLY (Serplulimab). This therapy is the first programmed death-1 inhibitor globally approved for extensive-stage small cell lung cancer and employs a dual mechanism targeting PD-L1 and PD-L2 with strong receptor internalization to enhance immune engagement. Its demonstrated survival benefit and significantly reduced cost compared with existing immunotherapies emphasize its clinical value and expand patient access to advanced cancer treatment in India.

Which Organizations Are Operating Within The Cancer Immunotherapy Market?

Major companies operating in the cancer immunotherapy market are Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc., Kura Oncology Inc.

Access The Complete Cancer Immunotherapy Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Which Region Has The Strongest Presence In The Cancer Immunotherapy Market?

North America was the largest region in the cancer immunotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Cancer Immunotherapy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp

Browse Through More Reports Similar to the Global Cancer Immunotherapy Market 2026, By The Business Research Company

Cancer Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Cellulars Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Allergy Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergy-immunotherapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Cancer Immunotherapy Market Expected To Reach Based On Its 2026 Value?

The cancer immunotherapy market size has experienced significant expansion recently. It is projected to increase from $124.09 billion in 2025 to $137.99 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.2%. The historical development of this market is attributable to breakthroughs in tumor immunology, a rising global incidence of cancer, the early success of monoclonal antibodies, increased oncology R&D funding, and regulatory approvals for checkpoint inhibitors.

The cancer immunotherapy market is anticipated to experience significant expansion in the coming years. Its valuation is projected to reach $210.39 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.1%. Factors contributing to this growth during the projection period include the increasing uptake of CAR T-cell therapies, the broadening scope into solid tumor treatments, heightened investment in cancer vaccines, the escalating need for targeted combination therapies, and favorable reimbursement frameworks for immunotherapy. Key trends expected within this forecast timeframe encompass the swift integration of immune checkpoint inhibitors, the expanding application of combination immunotherapy protocols, the proliferation of cell-based cancer treatments, an increased emphasis on individualized immunotherapy, and a rising volume of oncology clinical trials.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp

What Factors Are Contributing To The Growth Of The Cancer Immunotherapy Market?

An anticipated increase in cancer cases is poised to drive the growth of the cancer immunotherapy market. Globally, several elements contribute to this rise in cancer occurrences, such as tobacco use, alcohol consumption, obesity, inactive lifestyles, and various environmental influences. The increasing number of cancer cases is predicted to elevate the need for cancer immunotherapies, particularly as patients show a growing inclination to invest in medical interventions offering improved recovery prospects and reduced discomfort. For example, in July 2024, projections from Cancer Research UK, a UK-based cancer charity, indicate that cancer incidence rates in the United Kingdom are forecast to rise for the majority of cancer types between 2023-2025 and 2038-2040. These increases are expected to vary significantly, from less than 1% for breast cancer up to 50% for eye cancer. Conversely, a few cancer types are anticipated to show a decrease, with reductions ranging from 2% for lung cancer to 27% for mesothelioma. Consequently, the growing prevalence of cancer is set to enhance the demand for cancer immunotherapy over the forecast period.

How Is The Cancer Immunotherapy Market Broken Down By Segment Categories?

The cancer immunotherapy market covered in this report is segmented –

1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy

2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma

3) By End User: Hospitals, Cancer Research Centers, Clinics

Subsegments:

1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies

2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists

4) By Vaccines: Therapeutic Cancer Vaccines

5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy

What Market Trends Are Affecting The Cancer Immunotherapy Market?

Major companies operating in the cancer immunotherapy market are concentrating on developing innovative solutions, such as PD-1 immunotherapies, to extend the availability of advanced immune-based treatment options for patients suffering from hard-to-treat cancers. A PD-1 immunotherapy is an immune checkpoint-targeting treatment designed to stimulate antitumor immune activity by blocking interactions within the programmed death-1 pathway. For instance, in August 2025, Intas Pharmaceuticals, an India-based pharmaceutical firm specializing in oncology and biologics, introduced HETRONIFLY (Serplulimab). This therapy stands as the first programmed death-1 inhibitor approved globally for extensive-stage small cell lung cancer, employing a dual mechanism that targets PD-L1 and PD-L2 with strong receptor internalization to enhance immune engagement. Its proven survival benefit and significantly reduced cost compared with existing immunotherapies emphasize its clinical worth and broaden patient access to advanced cancer treatment in India.

Which Players Are Present In The Cancer Immunotherapy Market Space?

Major companies operating in the cancer immunotherapy market are Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc., Kura Oncology Inc.

Get The Full Cancer Immunotherapy Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Which Region Is The Leading Market For The Cancer Immunotherapy Market?

North America was the largest region in the cancer immunotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cancer Immunotherapy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Browse Through More Reports Similar to the Global Cancer Immunotherapy Market 2026, By The Business Research Company

Cancer Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Cellulars Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Allergy Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergy-immunotherapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Cancer Immunotherapy Market Between 2026 And 2030?

The cancer immunotherapy market size has shown swift expansion in recent years. It is forecast to increase from $124.09 billion in 2025 to $137.99 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.2%. This past growth can be ascribed to significant discoveries in tumor immunology, an escalating global incidence of cancer, the initial achievements of monoclonal antibodies, augmented funding for oncology research and development, and regulatory endorsements for checkpoint inhibitors.

The cancer immunotherapy market is projected to experience substantial expansion in the coming years. Its value is anticipated to reach $210.39 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.1%. This growth during the forecast period is attributable to factors such as the increasing uptake of CAR T-cell therapies, the broadening scope into solid tumor indications, heightened investment in cancer vaccines, a surge in demand for targeted combination therapies, and favorable reimbursement policies for immunotherapy. Key trends anticipated during the same period encompass the swift adoption of immune checkpoint inhibitors, an escalating reliance on combination immunotherapy regimens, the proliferation of cell-based cancer treatments, an intensified focus on personalized immunotherapy approaches, and a growing volume of oncology clinical trials.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp

What Key Drivers Are Influencing The Growth Of The Cancer Immunotherapy Market?

The increasing occurrence of cancer is anticipated to drive growth in the cancer immunotherapy market. Global cancer cases are escalating due to factors such as tobacco use, alcohol consumption, obesity, inactive lifestyles, and various environmental influences. This surge in cancer diagnoses is projected to heighten the demand for cancer immunotherapies, as patients increasingly opt for medical interventions promising improved recovery rates and reduced discomfort. For example, projections from Cancer Research UK, a UK-based cancer charity, indicate that in July 2024, cancer incidence rates in the United Kingdom are forecast to rise for the majority of cancer types between 2023-2025 and 2038-2040. These increases vary, from less than 1% for breast cancer up to 50% for eye cancer. Conversely, a few cancer types are expected to show a decrease, with declines ranging from 2% for lung cancer to 27% for mesothelioma. Consequently, the rising cancer incidence is poised to stimulate the demand for cancer immunotherapy throughout the forecast period.

Which Market Segments Are Examined In The Cancer Immunotherapy Market Study?

The cancer immunotherapy market covered in this report is segmented –

1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy

2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma

3) By End User: Hospitals, Cancer Research Centers, Clinics

Subsegments:

1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies

2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists

4) By Vaccines: Therapeutic Cancer Vaccines

5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy

Which Trends Are Influencing The Cancer Immunotherapy Market?

Leading companies in the cancer immunotherapy market are concentrating on developing innovative solutions, such as PD-1 immunotherapies, to expand access to advanced immune-based treatment options for patients suffering from hard-to-treat cancers. A PD-1 immunotherapy functions as an immune checkpoint-targeting treatment designed to stimulate antitumor immune activity by impeding programmed death-1 pathway interactions. For instance, in August 2025, Intas Pharmaceuticals, an India-based pharmaceutical company specializing in oncology and biologics, released HETRONIFLY (Serplulimab). This therapy stands as the first programmed death-1 inhibitor approved globally for extensive-stage small cell lung cancer and operates through a dual mechanism targeting PD-L1 and PD-L2, featuring strong receptor internalization to boost immune engagement. Its demonstrated survival benefit and notably reduced cost compared with existing immunotherapies emphasize its clinical worth and broaden patient access to advanced cancer treatment in India.

Who Are The Primary Competitors In The Cancer Immunotherapy Market?

Major companies operating in the cancer immunotherapy market are Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc., Kura Oncology Inc.

Read the full cancer immunotherapy market report here:

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Cancer Immunotherapy Market?

North America was the largest region in the cancer immunotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cancer Immunotherapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=6768&type=smp

Browse Through More Reports Similar to the Global Cancer Immunotherapy Market 2026, By The Business Research Company

Cancer Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Cellulars Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Allergy Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergy-immunotherapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Cancer Immunotherapy Market Between 2026 And 2030?

The cancer immunotherapy market size has shown swift expansion in recent years. It is forecast to increase from $124.09 billion in 2025 to $137.99 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.2%. This past growth can be ascribed to significant discoveries in tumor immunology, an escalating global incidence of cancer, the initial achievements of monoclonal antibodies, augmented funding for oncology research and development, and regulatory endorsements for checkpoint inhibitors.

The cancer immunotherapy market is projected to experience substantial expansion in the coming years. Its value is anticipated to reach $210.39 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.1%. This growth during the forecast period is attributable to factors such as the increasing uptake of CAR T-cell therapies, the broadening scope into solid tumor indications, heightened investment in cancer vaccines, a surge in demand for targeted combination therapies, and favorable reimbursement policies for immunotherapy. Key trends anticipated during the same period encompass the swift adoption of immune checkpoint inhibitors, an escalating reliance on combination immunotherapy regimens, the proliferation of cell-based cancer treatments, an intensified focus on personalized immunotherapy approaches, and a growing volume of oncology clinical trials.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp

What Key Drivers Are Influencing The Growth Of The Cancer Immunotherapy Market?

The increasing occurrence of cancer is anticipated to drive growth in the cancer immunotherapy market. Global cancer cases are escalating due to factors such as tobacco use, alcohol consumption, obesity, inactive lifestyles, and various environmental influences. This surge in cancer diagnoses is projected to heighten the demand for cancer immunotherapies, as patients increasingly opt for medical interventions promising improved recovery rates and reduced discomfort. For example, projections from Cancer Research UK, a UK-based cancer charity, indicate that in July 2024, cancer incidence rates in the United Kingdom are forecast to rise for the majority of cancer types between 2023-2025 and 2038-2040. These increases vary, from less than 1% for breast cancer up to 50% for eye cancer. Conversely, a few cancer types are expected to show a decrease, with declines ranging from 2% for lung cancer to 27% for mesothelioma. Consequently, the rising cancer incidence is poised to stimulate the demand for cancer immunotherapy throughout the forecast period.

Which Market Segments Are Examined In The Cancer Immunotherapy Market Study?

The cancer immunotherapy market covered in this report is segmented –

1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy

2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma

3) By End User: Hospitals, Cancer Research Centers, Clinics

Subsegments:

1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies

2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists

4) By Vaccines: Therapeutic Cancer Vaccines

5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy

Which Trends Are Influencing The Cancer Immunotherapy Market?

Leading companies in the cancer immunotherapy market are concentrating on developing innovative solutions, such as PD-1 immunotherapies, to expand access to advanced immune-based treatment options for patients suffering from hard-to-treat cancers. A PD-1 immunotherapy functions as an immune checkpoint-targeting treatment designed to stimulate antitumor immune activity by impeding programmed death-1 pathway interactions. For instance, in August 2025, Intas Pharmaceuticals, an India-based pharmaceutical company specializing in oncology and biologics, released HETRONIFLY (Serplulimab). This therapy stands as the first programmed death-1 inhibitor approved globally for extensive-stage small cell lung cancer and operates through a dual mechanism targeting PD-L1 and PD-L2, featuring strong receptor internalization to boost immune engagement. Its demonstrated survival benefit and notably reduced cost compared with existing immunotherapies emphasize its clinical worth and broaden patient access to advanced cancer treatment in India.

Who Are The Primary Competitors In The Cancer Immunotherapy Market?

Major companies operating in the cancer immunotherapy market are Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc., Kura Oncology Inc.

Read the full cancer immunotherapy market report here:

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Cancer Immunotherapy Market?

North America was the largest region in the cancer immunotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cancer Immunotherapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=6768&type=smp

Browse Through More Reports Similar to the Global Cancer Immunotherapy Market 2026, By The Business Research Company

Cancer Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Cellulars Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Allergy Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergy-immunotherapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the cancer immunotherapy market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Cancer Immunotherapy Market show for the 2026–2030 period?

The cancer immunotherapy market has experienced substantial expansion in recent years. This market is projected to grow from $124.09 billion in 2025 to reach $137.99 billion by 2026, driven by a compound annual growth rate (CAGR) of 11.2%. Historically, this expansion can be linked to significant breakthroughs in tumor immunology, an increasing global incidence of cancer, the early triumphs of monoclonal antibodies, augmented funding for oncology research and development, and the regulatory approval of checkpoint inhibitors.

The cancer immunotherapy market is anticipated to experience substantial growth over the next few years, with projections indicating it will reach $210.39 billion by 2030, driven by a compound annual growth rate (CAGR) of 11.1%. This expected expansion can be attributed to several factors, including the increasing adoption of CAR T-cell therapies, the broadening scope into solid tumor indications, higher investments in cancer vaccines, a growing demand for targeted combination therapies, and supportive reimbursement policies for immunotherapy. Furthermore, key trends in the forecast period involve the rapid embrace of immune checkpoint inhibitors, a rising utilization of combination immunotherapy regimens, the ongoing expansion of cell-based cancer treatments, a heightened focus on personalized immunotherapy, and an increasing number of oncology clinical trials.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp

What Drivers Are Shaping The Development Of The Cancer Immunotherapy Market?

The anticipated increase in cancer incidence is projected to propel the cancer immunotherapy market. Factors such as tobacco use, alcohol consumption, obesity, a sedentary lifestyle, and environmental influences are contributing to the global rise in cancer cases. This growth in cancer diagnoses is expected to heighten the demand for cancer immunotherapies, as patients are increasingly seeking medical treatments that offer better recovery and less pain. For instance, in July 2024, according to projections published by Cancer Research UK, a UK-based cancer charity, cancer incidence rates in the United Kingdom are forecasted to increase for most types between 2023-2025 and 2038-2040, with rises ranging from less than 1% for breast cancer to 50% for eye cancer. Conversely, a smaller number of cancers are expected to decline, with reductions ranging from 2% for lung cancer to 27% for mesothelioma. Therefore, the escalating cancer incidence is anticipated to boost demand for cancer immunotherapy during the forecast period.

Which Segments Are Contributing To The Growth Of The Cancer Immunotherapy Market?

The cancer immunotherapy market covered in this report is segmented –

1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy

2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma

3) By End User: Hospitals, Cancer Research Centers, Clinics

Subsegments:

1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies

2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists

4) By Vaccines: Therapeutic Cancer Vaccines

5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy

Which Trends Are Influencing The Performance And Direction Of The Cancer Immunotherapy Market?

Major companies operating in the cancer immunotherapy market are prioritizing the development of novel solutions, including PD-1 immunotherapies, to broaden access to advanced immune-based treatment options for individuals with hard-to-treat cancers. A PD-1 immunotherapy is a treatment specifically targeting immune checkpoints, engineered to stimulate antitumor immune activity by impeding programmed death-1 pathway interactions. For instance, in August 2025, Intas Pharmaceuticals, an India-based pharmaceutical company focused on oncology and biologics, launched HETRONIFLY (Serplulimab). This therapy is recognized as the first programmed death-1 inhibitor globally approved for extensive-stage small cell lung cancer, utilizing a dual mechanism that targets PD-L1 and PD-L2 with robust receptor internalization to enhance immune engagement. Its demonstrated survival benefit and considerably reduced cost compared to existing immunotherapies highlight its clinical worth and improve patient access to advanced cancer treatment in India.

Who Are The Primary Competitors In The Global Cancer Immunotherapy Market?

Major companies operating in the cancer immunotherapy market are Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc., Kura Oncology Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Cancer Immunotherapy Market?

North America was the largest region in the cancer immunotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cancer Immunotherapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=6768&type=smp

Browse Through More Reports Similar to the Global Cancer Immunotherapy Market 2026, By The Business Research Company

Cancer Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Cellulars Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Allergy Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergy-immunotherapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the cancer immunotherapy market from 2025–2034 with trusted insights from The Business Research Company

How Is The Cancer Immunotherapy Market Size Expected To Expand Over 2029-2034?

The cancer immunotherapy market size has experienced rapid expansion in recent years. It is projected to grow from $110.91 billion in 2024 to $124.09 billion in 2025, at a compound annual growth rate (CAGR) of 11.9%. The growth observed in the historical period can be attributed to the increasing prevalence of cancer, greater adoption of immunotherapy as an alternative to traditional therapy, expanding research and development efforts for the creation of targeted disease treatments, improved effectiveness and accuracy of more recent therapies, and a growing recognition of the limitations associated with conventional cancer treatments.

The cancer immunotherapy market is projected to undergo significant expansion in the coming years, with its size forecast to reach $189.5 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 11.2%. This projected growth is driven by various factors, including the increasing approval of innovative immunotherapies for cancer care, the rising demand for personalized medical approaches, an uptick in cancer diagnoses, greater investment in clinical trials aimed at introducing advanced treatments, and growing public awareness concerning cancer immunotherapy. Notable trends anticipated during this period encompass the rise of adoptive cell therapies, including CAR-T cells, the ongoing investigation into oncolytic viruses within cancer immunotherapy, the formulation of personalized cancer vaccines, the application of artificial intelligence in immunotherapy research, and an increased focus on real-world evidence and patient outcomes in guiding treatment decisions.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp

Which Market Factors Are Fueling The Cancer Immunotherapy Industry Growth?

The increasing occurrence of cancer is projected to drive the growth of the cancer immunotherapy market. Contributing elements to the worldwide increase in cancer diagnoses encompass tobacco use, alcohol consumption, obesity, inactive lifestyles, and various environmental influences. This escalation in cancer instances is anticipated to heighten the need for cancer immunotherapies, given that patients are progressively seeking medical interventions that offer improved recovery outcomes and less discomfort. For example, data from October 2023, sourced from the European Union Science Hub, which is the Belgium-based European Commission’s Joint Research Centre, indicated a 2.3% rise in new cancer diagnoses over the prior two years, totaling 2.74 million in 2022. Likewise, cancer-related deaths saw a 2.4% increase over the same two-year period. Consequently, the growing rate of cancer prevalence is projected to elevate the demand for cancer immunotherapy throughout the forecast period.

Which Categories Are Covered In The Cancer Immunotherapy Market Segmentation Analysis?

The cancer immunotherapy market covered in this report is segmented –

1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy

2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma

3) By End User: Hospitals, Cancer Research Centers, Clinics

Subsegments:

1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies

2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists

4) By Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy

Which Market Trends Are Expected To Define The Future Of The Cancer Immunotherapy Market?

A significant trend gaining traction in the cancer immunotherapy market is the utilization of advanced technologies. There has been an increase in new technologies and various therapeutic interventions designed to assist the immune system in identifying and attacking tumors, incorporating different methods and technologies such as immuno-oncology, cryoablation, bone marrow transplant, and radiation therapy. These technological innovations have the potential to considerably enhance cancer treatment and prospects for a cure. For instance, in October 2022, AstraZeneca plc, a UK-based pharmaceutical and biotechnology company, announced that it had secured approval for its Capivasertib in conjunction with Faslodex. This particular drug is a cancer immunotherapeutic created for the management of breast cancer, demonstrating effectiveness in cases of recurrence or progression on or after endocrine therapy in locally advanced or metastatic breast cancer with low or negative human epidermal growth factor receptor 2 (HER2).

Which Organizations Are At The Forefront Of The Cancer Immunotherapy Market?

Major companies operating in the cancer immunotherapy market include Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, 3D Signatures Inc., Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, Kura Oncology Inc., MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Pulse Biosciences Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Which Geographic Areas Are Driving Strong Demand For The Cancer Immunotherapy Market?

North America was the largest region in the cancer immunotherapy market in 2024 and is also expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=6768&type=smp

Browse Through More Reports Similar to the Global Cancer Immunotherapy Market 2025, By The Business Research Company

Pain Management Devices And Therapies Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pain-management-devices-and-therapies-global-market-report

Metabolomics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report

Isothermal Nucleic Acid Amplification Technology Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/isothermal-nucleic-acid-amplification-technology-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model